

William Shaw, Ph.D., Director 11813 West 77th Street, Lenexa, KS 66214 (913) 341-8949 Fax (913) 341-6207 www.GPL4U.com


Report Number:	Patient Info:	Samples	Date/Time
09-999	David Sample	Morning	11/07/2005 0800
Provider:	Age: 46 Gender: M	Noon	11/07/2005 1230
Just Hormones 232323 SW Hormone St.	Menopausal Status:	Evening	11/07/2005 1820
	None	Night	11/07/2005 2350
Mesa, AZ 85215	87654 NE Balanced Street Suffern, NJ 10901	Date Samples 11/10/2005	
	Phone: Not available	Date Results	11/11/2005

Result	Units	L	WR	н	Reference Range
<1.0	pg/ml		Χ		(1) 1.0-3.2 post-menopausal; (2) 1.0-10.8 pre-menopausal; (3) 1.5-10.0 replacement therapy; (4) <2.5 males
35.9	pg/ml		Χ		(1) 18-51 post-menopausal; (2) 127-446 pre-menopausal-luteal; (3) 500-3000 supplementation; (4) <94 males
35.9		X			(1) 200-600 females; (2) 200-300 males;
46.1	pg/ml		Χ		(1) 30.1-142.5 males; (2) 4.5-49 females; (3) 30-60 therapy females; (4) 250-350 therapy males;
61.3	pg/ml	X			(1) 137-336 males; (2) 106-300 females;
4.0	nmo/L	X			(1) 5.1-40.2; Optimal Range: 18-35*
4.7	nmo/L		Χ		(1) 2.1-15.7; Optimal Range: 6-12*
1.5	nmo/L	X			(1) 1.8-12; Optimal Range: 4-8*
< 0.3	nmo/L	X			(1) 0.9-9.2; Optimal Range: 2-6*
	<1.0 35.9 35.9 46.1 61.3 4.0 4.7	<1.0 pg/ml 35.9 pg/ml 35.9 46.1 pg/ml 61.3 pg/ml 4.0 nmo/L 1.5 nmo/L	<1.0 pg/ml 35.9 pg/ml 35.9 X 46.1 pg/ml 61.3 pg/ml X 4.0 nmo/L X 4.7 nmo/L 1.5 nmo/L X	<pre><1.0 pg/ml</pre>	<1.0 pg/ml X 35.9 pg/ml X 35.9 X 46.1 pg/ml X 61.3 pg/ml X 4.0 nmo/L X 4.7 nmo/L X 1.5 nmo/L X

^{*}DHEA, Testosterone and Estriol results are for investigational use only

L=Low (below reference range) WR=Within Range (within reference range) H= High (above reference range)

^{*} Apply only when all four cortisols are measured. Clinical interpretations may override these generalized optimal reference ranges.



Interpretations:

- The low Pg/E2 ratio is consistent with estrogen dominance, which increases the risk of prostate gland enlargement and cancer. Supplementation with topical progesterone to correct this relative deficiency is a consideration.
- Suboptimal testosterone is consistent with reported deficiency symptoms and is often associated with metabolic syndrome (insulin resistance). Fasting blood sugar and insulin levels may be warranted. Boosting the testosterone level is a consideration.
- DHEA level is consistent with the expected decline with age (adrenopause). The low DHEA level
 may warrant supplementation for optimal well-being. Note: Supplementation with DHEA may
 increase testosterone and/or estradiol levels.
- Diurnal cortisol pattern and reported symptoms are consistent with established (Phase 3) adrenal gland fatigue (hypoadrenia), although concomitant thyroid and/or iodine insufficiency cannot be ruled out.